Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2…
. First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SA…
Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts Level 1 clinical…
. MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product Rounds out MagnetOs portfolio to…
Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized contro…
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs pro…